NHF is expanding its work with the bleeding disorders community around the world.
PrintFriendly
-
Envisioning “Treatment for All” on World Hemophilia Day
-
HEMLIBRA® Receives Breakthrough Designation from FDA
The designation is for people with hemophilia A without inhibitors.
-
Grifols Announces 2017 Factor Product Donations to WFH Humanitarian Aid Program
The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B.
-
ICER Review of Emicizumab for People with Hemophilia A and Inhibitors
ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery innovations.
-
NHF CEO Shares Vision with Chapters
Val D. Bias spoke to the leaders of NHF’s 52-chapter networks at the NHF 2018 Chapter Leadership Seminar in San Francisco, California.
-
Apply Today for the 2018 Kevin Child Scholarship!
Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs.
-
NHF 70th: The Fight to Preserve ACA Patient Protections Goes On
2018 marks NHF’s 70th year as the bleeding disorders community’s chief advocate.
-
Statement from Genentech Regarding Hemlibra
Updated statement from Genentech on Hemlibra, March 28, 2018.